Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

AETERNA ZENTARIS ANNOUNCES EMA DECISION TO ACCEPT A MODIFICATION TO AN AGREED PEDIATRIC INVESTIGATION PLAN FOR MACIMORELIN

GlobeNewswire April 7, 2020

AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN

GlobeNewswire April 6, 2020

AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

GlobeNewswire March 30, 2020

AETERNA ZENTARIS ANNOUNCES SETTLEMENT OF PREVIOUSLY DISCLOSED CLASS-ACTION LAWSUIT

GlobeNewswire March 12, 2020

Aeterna Zentaris Announces Closing of $4.5 Million Registered Direct Offering Priced At-The-Market

GlobeNewswire February 21, 2020

Aeterna Zentaris Announces $4.5 Million Registered Direct Offering Priced At-The-Market

GlobeNewswire February 19, 2020

Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference

GlobeNewswire February 12, 2020

Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin

GlobeNewswire January 28, 2020

Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing

GlobeNewswire January 27, 2020

Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement

GlobeNewswire January 8, 2020

Aeterna Zentaris Announces Publication of GHD Management Guidelines

GlobeNewswire December 18, 2019

Aeterna Zentaris Announces 2020 Director Changes

GlobeNewswire December 16, 2019

Aeterna Zentaris Reports Third Quarter 2019 Financial and Operating Results

GlobeNewswire November 7, 2019

Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

GlobeNewswire October 4, 2019

Aeterna Zentaris Announces Closing of Approximately $5.0 Million Registered Direct Offering

GlobeNewswire September 24, 2019

Aeterna Zentaris Announces Pricing of Approximately $5.0 Million Registered Direct Offering

GlobeNewswire September 20, 2019

Aeterna Zentaris Announces Director Change

GlobeNewswire August 20, 2019

Aeterna Zentaris Reports Second Quarter 2019 Financial and Operating Results

GlobeNewswire August 13, 2019

Aeterna Zentaris Provides Corporate Update

GlobeNewswire June 6, 2019

Aeterna Zentaris Announces Results of Annual and Special Shareholders' Meeting

GlobeNewswire May 8, 2019